Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Radix Consulting files suit v. Biovail over sustained-release ketoprofen commissions.

  • News

Executive Summary

RADIX CONSULTING SUIT v. BIOVAIL OVER SUSTAINED-RELEASE KETOPROFEN focuses on the commissions Radix believes it is owed from Biovail's royalties on Oruvail. According to the suit, Biovail owed royalties to Radix under an agreement providing Radix a "10% commission on all royalty payments made to Biovail S.A. by Wyeth Laboratories" for the sale of sustained-release ketoprofen (Oruvail) in the U.S. The New York City consulting firm filed suit in New York State Supreme Court March 23.

Table

View full table

Tags:
Latest Headlines

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

Idorsia’s Novel Hypertension Pill Among Eight New Drugs To Win EMA Nod

AI Used In Drug R&D Likely Exempt From Tough EU AI Rules, Says EFPIA

EU Parliament OKs New Rules On Use Of Patient Data In Research

See All
UsernamePublicRestriction

Register

PS026292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By